Table 3. Association between the five miRNAs and melanoma cancer clinical characters.
Variables | miR-25 expression | miR-204 expression | miR-211 expression | miR-510 expression | miR-513c expression | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Low | High | P | Low | High | P | Low | High | P | Low | High | P | Low | High | P | |
Age | |||||||||||||||
<60 | 124 | 106 | 0.064 | 92 | 138 | <0.000* | 122 | 108 | 0.175 | 119 | 111 | 0.379 | 115 | 115 | 0.755 |
≥60 | 89 | 109 | 118 | 80 | 92 | 106 | 94 | 104 | 96 | 102 | |||||
Gender | |||||||||||||||
Female | 80 | 81 | 0.980 | 83 | 78 | 0.424 | 73 | 88 | 0.134 | 76 | 85 | 0.411 | 73 | 88 | 0.203 |
Male | 133 | 134 | 127 | 140 | 141 | 126 | 137 | 130 | 138 | 129 | |||||
T stage | |||||||||||||||
T1 + T2 | 75 | 62 | 0.157 | 54 | 83 | 0.004* | 84 | 53 | <0.000* | 79 | 58 | 0.003* | 75 | 62 | 0.037* |
T3 + T4 | 103 | 116 | 121 | 98 | 89 | 130 | 91 | 128 | 95 | 124 | |||||
Lymph node status | |||||||||||||||
N0 | 106 | 108 | 0.758 | 107 | 107 | 0.955 | 107 | 107 | 0.955 | 109 | 105 | 0.811 | 103 | 111 | 0.516 |
N1–2 | 82 | 89 | 86 | 85 | 85 | 86 | 85 | 86 | 88 | 83 | |||||
Mestasis | |||||||||||||||
M0 | 192 | 193 | 0.841 | 189 | 196 | 0.769 | 188 | 197 | 0.243 | 193 | 192 | 0.823 | 188 | 197 | 0.458 |
M1 | 10 | 11 | 11 | 10 | 13 | 8 | 10 | 11 | 12 | 9 | |||||
Clinical stage | |||||||||||||||
I + II | 107 | 95 | 0.166 | 102 | 100 | 0.715 | 97 | 105 | 0.512 | 97 | 105 | 0.738 | 93 | 109 | 0.250 |
III + IV | 84 | 99 | 89 | 94 | 94 | 89 | 91 | 92 | 95 | 88 | |||||
Breslow depth value (mm) | |||||||||||||||
<3 | 83 | 77 | 0.255 | 70 | 90 | 0.041* | 91 | 69 | <0.000* | 91 | 69 | <0.000* | 84 | 76 | 0.015* |
≥3 | 78 | 93 | 94 | 77 | 61 | 110 | 61 | 110 | 67 | 104 |
Notes.
P < 0.05 was considered statistically significant.